Department of Biological Chemistry, Weizmann Institute of Science, 76100 Rehovot, Israel.
J Biol Chem. 2012 Aug 24;287(35):29285-9. doi: 10.1074/jbc.C112.345397. Epub 2012 Jul 10.
The TrkA receptor tyrosine kinase induces death in medulloblastoma cells via an interaction with the cerebral cavernous malformation 2 (CCM2) protein. We used affinity proteomics to identify the germinal center kinase class III (GCKIII) kinases STK24 and STK25 as novel CCM2 interactors. Down-modulation of STK25, but not STK24, rescued medulloblastoma cells from NGF-induced TrkA-dependent cell death, suggesting that STK25 is part of the death-signaling pathway initiated by TrkA and CCM2. CCM2 can be phosphorylated by STK25, and the kinase activity of STK25 is required for death signaling. Finally, STK25 expression in tumors is correlated with positive prognosis in neuroblastoma patients. These findings delineate a death-signaling pathway downstream of neurotrophic receptor tyrosine kinases that may provide targets for therapeutic intervention in pediatric tumors of neural origin.
原肌球蛋白受体酪氨酸激酶(TrkA)通过与脑动静脉畸形 2 号(CCM2)蛋白相互作用诱导成神经管细胞瘤细胞死亡。我们利用亲和蛋白质组学鉴定了生殖中心激酶 III 类(GCKIII)激酶 STK24 和 STK25 是 CCM2 的新的相互作用蛋白。下调 STK25,但不是 STK24,可以挽救成神经管细胞瘤细胞免受 NGF 诱导的 TrkA 依赖性细胞死亡,表明 STK25 是由 TrkA 和 CCM2 启动的死亡信号通路的一部分。CCM2 可被 STK25 磷酸化,并且 STK25 的激酶活性对于死亡信号是必需的。最后,神经母细胞瘤患者肿瘤中 STK25 的表达与良好的预后相关。这些发现描绘了神经营养受体酪氨酸激酶下游的死亡信号通路,这可能为儿科神经来源肿瘤的治疗干预提供了靶点。